Cargando…
Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease
BACKGROUND: We have demonstrated previously that enzymatically degraded low‐density lipoprotein (eLDL) is an essential causative component for the initiation of atherosclerosis. Here, we investigated the different stages of human aortic valve sclerosis for the presence of eLDL and effectors of the i...
Autores principales: | Twardowski, Laura, Cheng, Fei, Michaelsen, Jens, Winter, Stefan, Hofmann, Ute, Schaeffeler, Elke, Müller, Simon, Sonnenberg, Maike, Steuer, Kristin, Ott, German, Schwab, Matthias, Franke, Ulrich F. W., Torzewski, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845139/ https://www.ncbi.nlm.nih.gov/pubmed/26475297 http://dx.doi.org/10.1161/JAHA.115.002156 |
Ejemplares similares
-
Lipoprotein(a)-Associated Molecules Are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis
por: Torzewski, Michael, et al.
Publicado: (2017) -
Pro-Calcifying Role of Enzymatically Modified LDL (eLDL) in Aortic Valve Sclerosis via Induction of IL-6 and IL-33
por: Witz, Annemarie, et al.
Publicado: (2023) -
Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)
por: Nies, Anne T., et al.
Publicado: (2011) -
Variants of PEAR1 Are Associated With Outcome in Patients With ACS and Stable CAD Undergoing PCI
por: Stimpfle, Fabian, et al.
Publicado: (2018) -
Pharmacogenomics: a key component of personalized therapy
por: Schwab, Matthias, et al.
Publicado: (2012)